Remove 2009 Remove Drug Pricing Remove Pharmaceutical Companies
article thumbnail

Divest to invest: the new normal in biopharma?

European Pharmaceutical Review

This heightened focus from regulators is shifting the type of deals pharmaceutical companies are willing to execute, Baral noted. These mega deals created behemoth companies that needed to spread capital too thin and included redundancies due to unrealised synergies.

article thumbnail

Is India capable of ensuring equitable access to biopharmaceuticals?

Express Pharma

What’s more, with many key biologics scheduled to lose patent protection in this decade, Indian pharmaceutical companies ought to seize this opportunity and leverage innovative technologies to introduce quality and way more affordable biosimilars in the domestic as well as global markets. appeared first on Express Pharma.